Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Shun Ichi Isa"'
Autor:
Yoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, Daijiro Harada, Shun-ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Atsuhisa Tamura, Masahiko Ando, Yasuhiro Koh
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background/Aim For patients treated with osimertinib as first-line therapy, there have been no studies comparing both progression-free survival (PFS) and overall survival (OS) according to performance status (PS). Furthermore, no studies hav
Externí odkaz:
https://doaj.org/article/4a44b3e2a4f646eaa098c5c76afb27b7
Autor:
Koichi Sato, Hiroaki Akamatsu, Yasuhiro Koh, Koichi Ogawa, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Chiyoe Kitagawa, Tomoya Kawaguchi, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background KRAS-mutated non-small cell lung cancer (NSCLC) accounts for 23–35% and 13–20% of all NSCLCs in white patients and East Asians, respectively, and is therefore regarded as a major therapeutic target. However, its epidemiology a
Externí odkaz:
https://doaj.org/article/1c2b486e0e1f4300a4ecaaa697d58abe
Autor:
Yoshiya Matsumoto, Tomoya Kawaguchi, Masaru Watanabe, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Chiyoe Kitagawa, Naoki Yoshimoto, Yasuhiro Koh
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Many previous studies have demonstrated that minor-frequency pretreatment T790M mutation (preT790M) could be detected by ultrasensitive methods in a considerable number of treatment-naïve, epidermal growth factor receptor (EGFR)-
Externí odkaz:
https://doaj.org/article/844359ba1f3942419f2d7778d0d8115c
Autor:
Akihiro Tamiya, Yasuhiro Koh, Shun‐ichi Isa, Akihito Kubo, Masahiko Ando, Hideo Saka, Naoki Yoshimoto, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Osamu Kawashima, Motohiro Yamashita, Kazuhiko Kataoka, Mitsuhiro Takenoyama, Yukiyasu Takeuchi, Katsuya Watanabe, Akihide Matsumura, Tomoya Kawaguchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 7, Pp 2343-2351 (2020)
Abstract Background To report the follow up data and clinical outcomes of the JME study (UMIN 000008177), a prospective, multicenter, molecular epidemiology examination of 876 surgically resected non‐small‐cell lung cancer (NSCLC) cases, and the
Externí odkaz:
https://doaj.org/article/5683b6fa5c354da5939ae03f12b109d8
Autor:
Masahiko Ando, Yoshihiko Taniguchi, Akihiro Tamiya, Akihide Matsumura, Koichi Ogawa, Yasuhiro Koh, Hiroyasu Kaneda, Motohiro Izumi, Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Naoki Yoshimoto, Akihito Kubo, Shun-ichi Isa, Hideo Saka, Tomoya Kawaguchi
Publikováno v:
BMJ Open, Vol 10, Iss 9 (2020)
Externí odkaz:
https://doaj.org/article/21d6aa93cb0a46079c661df2bf121902
Autor:
Masaru Watanabe, Tomoya Kawaguchi, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Hideo Saka, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Osamu Kawashima, Motohiro Yamashita, Kazuhiko Kataoka, Yukito Ichinose, Yukiyasu Takeuchi, Katsuya Watanabe, Akihide Matsumura, Yasuhiro Koh
Publikováno v:
EBioMedicine, Vol 21, Iss C, Pp 86-93 (2017)
Epidermal growth factor receptor (EGFR) mutations have been used as the strongest predictor of effectiveness of treatment with EGFR tyrosine kinase inhibitors (TKIs). Three most common EGFR mutations (L858R, exon 19 deletion, and T790M) are known to
Externí odkaz:
https://doaj.org/article/38c362f4c73e4f60970434713501eaf5
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Figures S1-8. Figure S1: Flowchart for mutation call. Figure S2: Quantification of performance of ddPCR analysis for EGFR T790M mutation. Figure S3: Analytical sensitivity of 0.001% for the ddPCR assay. Figure S4: Determination of false
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4242036600537831c53f664f345297d5
https://doi.org/10.1158/1078-0432.22456137.v1
https://doi.org/10.1158/1078-0432.22456137.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Purpose: The resistance to the EGFR tyrosine kinase inhibitors (TKI) is a major concern in non–small cell lung cancer (NSCLC) treatment. T790M mutation in EGFR accounts for nearly 50% of the acquired resistance to EGFR-TKIs. Earlier studies suggest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b3ad8790d0f4439ce3f54024f02594
https://doi.org/10.1158/1078-0432.c.6523212.v1
https://doi.org/10.1158/1078-0432.c.6523212.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Materials and Methods, Reference and Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cca6562ace6fa0272ed1b5b35964ddd
https://doi.org/10.1158/1078-0432.22456140.v1
https://doi.org/10.1158/1078-0432.22456140.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Tables S1-5. Table S1: Primers and probes used for droplet digital PCR (ddPCR). Table S2: Determination of the limit of blank (LOB) from wild-type control DNA, normal human genomic DNA, and EGFR wild-type A549 genomic DNA. Table S3: Det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::520406ecc177aca83747293358d78716
https://doi.org/10.1158/1078-0432.22456134.v1
https://doi.org/10.1158/1078-0432.22456134.v1